When was EndoClot Plus founded?

EndoClot Plus was founded in 2014.

Where is EndoClot Plus located?

EndoClot Plus is headquartered in Suzhou, China.

Where does EndoClot Plus rank among its competitors?

EndoClot Plus ranks 10th amongst 18 active competitors, of which 2 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Neptune Medical, which secured $97M in Aug, 2024.

Who are the top competitors of EndoClot Plus?

EndoClot Plus' top competitors include Creo Medical, Neptune Medical and LeoMed. Among them, Neptune Medical secured the most recent funding round in August, 2024.

EndoClot Plus - 2026 Company Profile, Team & Competitors

EndoClot Plus is an unfunded company based in Suzhou (China), founded in 2014 by James Ji. It operates as a Provider of the medical device for treating bleeding in the gastrointestinal tract. EndoClot Plus has not raised any funding yet. The company has 18 active competitors, including 2 funded and 2 that have exited. Its top competitors include companies like Creo Medical, Neptune Medical and LeoMed.

Company Details

Provider of the medical device for treating bleeding in the gastrointestinal tract. The company offers its proprietary products like EndoClot Polysaccharide Hemostatic System which use to spraying proprietary powder to the wound during endoscopy. EndoClot Adhesive which is a single-use device that consists of Adhesive Hemostatic Polymer (AHP) and EndoClot Submucosal Injection System (SIS) which consists of the Absorbable Modified Polymer (AMP) derived from plant starch particles which can be used in the treatment of early-stage cancers or other gastrointestinal mucosal lesions among others.

Key Metrics

Founded Year

2014

Location

Suzhou, China

Stage

Unfunded

Ranked

10^th among 18 active competitors

Similar Companies

Creo Medical & 19 more

View EndoClot Plus' full profile

EndoClot Plus has not raised any funding rounds yet.

The founders of EndoClot Plus is James Ji.

Here are the details of EndoClot Plus' key team members:

James Ji: Founder of EndoClot Plus.
Contact Info: 1 email address

View details of EndoClot Plus's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of EndoClot Plus include Creo Medical, Neptune Medical and LeoMed. Here is the list of Top 10 competitors of EndoClot Plus, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Creo Medical 2003, Chepstow (United Kingdom), Public	Developer of electrosurgical system and range of flexible endoscopic instruments	$20.8M	Finance Wales, Pentax Medical & 4 others	61/100
2nd	Neptune Medical 2016, Burlingame (United States), Series D	Manufacturer of dynamic rigidizing overtubes for enhanced endoscope control during procedures	$97M	Sonder Capital, Mighty Capital & 4 others	54/100
3rd	LeoMed 2011, Changzhou (China), Series A	Developer of Vascular and Gastrointestinal medical devices	$15.5M	Cowin Capital, CICC	49/100
4th	OverStitch 2013, Austin (United States), Unfunded	Provider of therapy for endoscopic suturing	-	-	47/100
5th	Torax Medical 2002, Minneapolis (United States), Acqui-Hired	Products to restore human sphincter function	$103M	Piper Jaffray, Mayo Clinic Business Accelerator ... & 5 others	34/100
6th	MI Devices 2013, Kottayam (India), Unfunded	Devices for minimally invasive procedures especially in the field of Gastroenterology	-	-	30/100
7th	Interscope 2013, Worcester (United States), Unfunded	Interscope Med: Advancing endoscopic solutions for tissue resection and necrosectomy	-	-	29/100
8th	XION Medical 1992, Berlin (Germany), Public	Products and instruments foe endoscopy	-	Brandenburg Capital	29/100
9th	HyGIeaCare 2014, Austin (United States), Deadpooled	Colonoscopy preparation device	$16.3M	OTV	27/100
10th	EndoClot Plus 2014, Suzhou (China), Unfunded	Provider of the medical device for treating bleeding in the gastrointestinal tract	-	-	27/100